VCG
BIIB icon

Vantage Consulting Group’s Biogen BIIB Stock Holding History

Vantage Consulting Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,005
Closed -$233K – 24
2024
Q2 		$233K Sell
1,005
-60
-6% -$13K 0.17% 135
2024
Q1 		$230K Buy
1,065
+86
+9% +$20.1K 0.15% 156
2023
Q4 		$253K Buy
979
+80
+9% +$19.6K 0.17% 106
2023
Q3 		$231K Buy
899
+157
+21% +$42K 0.15% 142
2023
Q2 		$211K Sell
742
-193
-21% -$57.5K 0.12% 190
2023
Q1 		$260K Buy
935
+89
+11% +$24.6K 0.15% 133
2022
Q4 		$234K Sell
846
-362
-30% -$102K 0.14% 151
2022
Q3 		$323K Sell
1,208
-10
-0.8% -$2.12K 0.19% 64
2022
Q2 		$248K Buy
1,218
+58
+5% +$11.9K 0.14% 129
2022
Q1 		$244K Buy
1,160
+42
+4% +$9.13K 0.1% 155
2021
Q4 		$268K Buy
1,118
+305
+38% +$78.4K 0.07% 159
2021
Q3 		$230K Buy
813
+235
+41% +$77K 0.05% 160
2021
Q2 		$200K Buy
+578
New +$175K 0.03% 200
2021
Q1 		– Sell
-303
Closed -$74K – 285
2020
Q4 		$74K Buy
+303
New +$78.2K 0.01% 281

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vantage Consulting Group's BIIB Position: Q3 2024 in Review

Vantage Consulting Group sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,005 shares — an estimated $233K sold.

Vantage Consulting Group first reported a position in BIIB in Q4 2020 and held it in 14 quarters. The position peaked at $323K in Q3 2022. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Vantage Consulting Group reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • Vantage Consulting Group sold 1,005 Biogen shares in Q3 2024, an estimated $233K.
  • Vantage Consulting Group first reported a position in Biogen in Q4 2020 and held it in 14 quarters.
  • Vantage Consulting Group's Biogen position peaked at $323K in Q3 2022.
  • 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.